Symbicort Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Symbicort Supply in 2026

Symbicort (budesonide/formoterol) remains one of the most widely prescribed ICS/LABA combination inhalers in the United States, used for maintenance treatment of asthma (ages 6+) and COPD. Over the past several years, intermittent supply disruptions have affected patient access and created challenges for prescribers.

This article provides a concise, provider-focused overview of the current Symbicort supply situation, prescribing considerations, available alternatives, and tools to support your patients.

Shortage Timeline

Understanding how we got here helps contextualize the current landscape:

• 2023: Initial supply disruptions reported across multiple inhaler brands, driven by manufacturing facility retooling for updated propellant systems and post-pandemic supply chain recovery challenges.
• 2024: Intermittent shortages continued. The FDA monitored the situation but Symbicort was not placed on the critical shortage list. Wholesaler allocation limits created uneven distribution, with some regions more affected than others.
• 2025: Generic budesonide/formoterol inhalers (including Breyna) entered the market, easing demand pressure on brand-name Symbicort. Supply improved but remained inconsistent in certain areas.
• 2026 (current): Symbicort is not on the FDA's critical shortage list. Generic availability has improved the overall supply picture, though some pharmacies — particularly large chains during peak respiratory season — continue to report intermittent stockouts.

Prescribing Implications

The fluctuating availability of Symbicort has several practical implications for prescribers:

Generic Substitution

Generic budesonide/formoterol inhalers are now FDA-approved and available. Unless you write "dispense as written" (DAW), most pharmacies will automatically substitute the generic when brand-name Symbicort is unavailable or when the generic is on the patient's formulary. The generic products have demonstrated bioequivalence and use the same delivery mechanism.

Therapeutic Interchange Considerations

When neither brand-name Symbicort nor its generic is available, therapeutic alternatives include:

• Advair Diskus/HFA (Fluticasone/Salmeterol) — Available in multiple strengths; generic (Wixela Inhub) widely available. Note: different device type (DPI vs MDI) may require patient education.
• Breo Ellipta (Fluticasone Furoate/Vilanterol) — Once-daily dosing may improve adherence. Approved for asthma (18+) and COPD.
• Dulera (Mometasone/Formoterol) — Contains the same LABA (formoterol) as Symbicort; approved for asthma only (5+).

When switching, consider dose equivalence tables — the corticosteroid potencies differ across products. The GINA and GOLD guidelines provide dosing equivalence recommendations.

Step Therapy and Prior Authorization

Many insurance plans require step therapy for ICS/LABA combinations. If switching a patient to an alternative, verify formulary coverage before prescribing to avoid prior authorization delays. Patients already established on Symbicort may have an easier path to approval for its generic than for a different therapeutic class.

Current Availability Picture

Based on pharmacy and distribution data:

• Brand-name Symbicort: Generally available but with intermittent regional stockouts, particularly during October–February respiratory season
• Generic budesonide/formoterol (Breyna, authorized generics): Increasingly well-stocked; becoming the default dispensed product at many pharmacies
• 160/4.5 mcg strength: More commonly stocked than 80/4.5 mcg at most pharmacies

Independent pharmacies and mail-order pharmacies tend to have more consistent availability than large retail chains.

Cost and Access Considerations

Patient cost burden remains a significant factor in adherence:

• Brand-name Symbicort: $350–$450 cash price per inhaler
• Generic budesonide/formoterol: $200–$350 cash; $150–$250 with discount cards
• Insurance copays: Typically $20–$75 for preferred formulary products

For uninsured or underinsured patients:

• AstraZeneca Savings Card: Eligible commercially insured patients may pay as little as $0
• AZ&Me Patient Assistance Program: Free medication for qualifying patients (income-based). Application at azandmeapp.com or 1-800-292-6363
• Discount cards: GoodRx, SingleCare, and RxSaver can reduce generic pricing significantly

For detailed patient-facing cost information, you can direct patients to our guide on saving money on Symbicort.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability challenges:

• Medfinder for Providers — Real-time pharmacy inventory lookup. Help patients identify which pharmacies near them have Symbicort or its generic in stock before they leave your office.
• FDA Drug Shortage Database — Monitor official shortage status at accessdata.fda.gov
• ASHP Drug Shortage Resource Center — Additional shortage monitoring and clinical guidance

Proactively checking availability at the point of prescribing can prevent patient frustration and improve fill rates.

Looking Ahead

The outlook for Symbicort supply in 2026 is cautiously optimistic:

• Generic competition is increasing, which should stabilize both supply and pricing
• Manufacturing capacity for inhaler products continues to expand
• Propellant transition-related disruptions are largely behind us
• New ICS/LABA products in the pipeline may further diversify treatment options

However, seasonal demand spikes and regional distribution imbalances will likely continue to cause localized shortages. Building flexibility into your prescribing — including familiarity with therapeutic alternatives and generic options — remains the best strategy.

Final Thoughts

Symbicort supply has stabilized significantly compared to 2023-2024, but providers should remain prepared for intermittent disruptions. Leveraging generic options, maintaining awareness of therapeutic alternatives, and using tools like Medfinder can help ensure your patients maintain uninterrupted access to their maintenance inhaler therapy.

For a complementary guide on helping patients locate Symbicort, see our provider's guide to finding Symbicort in stock.